Notice2026-05694
Office of the Director, Notice of Charter Renewal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 24, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 56 (Tuesday, March 24, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 56 (Tuesday, March 24, 2026)]
[Notices]
[Pages 14031-14034]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-05694]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, Notice of Charter Renewal
In accordance with Title 41 of the U.S. Code of Federal
Regulations, Section 102-3.65(a), notice is hereby given that the
charter for the National Cancer Institute Clinical Trials and
Translational Research Advisory Committee (CTAC) is being renewed for
an additional two-year period on April 14, 2026.
It is determined that the CTAC is in the public interest in
connection with the performance of duties imposed on the National
Institutes of Health by law, and that these duties can best be
performed through the advice and counsel of this group.
The Public Interest Determination follows:
[[Page 14032]]
National Institutes of Health
National Cancer Institute Clinical Trials and Translational Research
Advisory Committee (CTAC)
Public Interest Determination
Pursuant to 41 CFR 102-3.60(a), to establish, renew, reestablish,
or merge a discretionary (agency discretion) advisory committee, an
agency must first consult with the General Services Administration's
Committee Management Secretariat (the Secretariat) and, as part of the
consultation, provide a written public interest determination approved
by the head of the agency to the Secretariat with a copy to the Office
of Management and Budget. In addition, pursuant to 41 CFR 102-3.35, an
agency shall follow the same consultation process and document in
writing the same determination of need before creating a subcommittee
under a discretionary committee that is not made up entirely of members
of a parent advisory committee.
Information on the following factors for the committee is provided
to the Secretariat to demonstrate that renewing the committee is in the
public interest:
1. Annual budget: The projected total committee cost for FY 2026 is
$121,213.
a. Federal personnel on a full-time equivalent (FTE) basis: The
estimated annual person-years of staff support required is 0.4 FTE at
an estimated annual cost of $83,355.
b. Other Federal internal costs: The estimated annual cost of other
Federal internal expenses is $4,727.
c. Proposed payments to members: The estimated annual payments for
19 non-Federal members are $4,600. The estimated prorated salary of two
Federal members is $1,496.
d. Proposed number of members: The committee will consist of up to
25 non-Federal members, in addition to Federal ex officio members.
e. Reimbursable costs: The estimated reimbursable costs, including
members' travel expenses, are $27,035.
2. If applicable, the total dollar value of grants expected to be
recommended during the fiscal year: N/A.
3. Criteria for selecting members to ensure the committee has the
necessary expertise and fairly balanced membership:
The Committee will consist of up to 25 non-Federal members
appointed by the National Cancer Institute (NCI) Director as well as
Federal ex officio members. Non-Federal members must be eligible to
serve as Special Government Employees (SGEs) and will serve as SGEs as
defined by 18 U.S.C. Sec. 202.
The Chair will be selected by the NCI Director from among the non-
Federal members. When necessary, up to four members may hold concurrent
membership on the National Cancer Advisory Board and/or the NCI Board
of Scientific Counselors.
Members will be recognized authorities knowledgeable in fields
including community oncology; surgical, medical, radiation, and
pediatric oncology; patient advocacy; extramural clinical
investigation; regulatory agencies; pharmaceutical industry; public
health; clinical trial design, management, and evaluation; drug
development and developmental therapeutics; cancer education; cancer
information services; community outreach; vaccine development; cellular
and molecular oncology; clinical, basic, and translational research;
cancer center administration; cancer biology and diagnosis; cancer
epidemiology; chemotherapy; oncology health care delivery;
pharmacology; pathology; biostatistics; quality of life; health care
outcomes; pain management; cancer treatment and restorative care; and
education of health professionals.
Non-Federal members, including the Chair, may serve overlapping
five-year terms. Members serving concurrently on the National Cancer
Advisory Board or the NCI Board of Scientific Counselors will serve no
longer than the duration of their respective board terms. An appointed
member may continue to serve after term expiration until a successor is
appointed.
Non-voting ex officio members may include officials from the Food
and Drug Administration (FDA), Centers for Medicare & Medicaid Services
(CMS), Department of Defense (DoD), Department of Veterans Affairs
(VA), and other Federal officials as appointed by the NCI Director.
4. List of all other Federal advisory committees of the agency:
<bullet> Advisory Committee on Research on Women's Health
<bullet> Advisory Committee to the Director, National Institutes of
Health
<bullet> Advisory Council on Parkinson's Research, Care and Services
<bullet> Aging and Neurodegeneration Integrated Review Group
<bullet> AIDS Research Advisory Committee, NIAID
<bullet> Applied Immunology and Disease Control Integrated Review Group
<bullet> Applied Therapeutics for Cancer Integrated Review Group
<bullet> Biobehavioral and Behavioral Processes Integrated Review Group
<bullet> Bioengineering Sciences & Technologies Integrated Review Group
<bullet> Biological Chemistry and Macromolecular Biophysics Integrated
Review Group
<bullet> Board of Regents of the National Library of Medicine
<bullet> Board of Scientific Counselors Eunice Kennedy Shriver National
Institute of Child Health and Human Development
<bullet> Board of Scientific Counselors National Human Genome Research
Institute
<bullet> Board of Scientific Counselors of the National Heart, Lung,
and Blood Institute
<bullet> Board of Scientific Counselors of the NIH Clinical Center
<bullet> Board of Scientific Counselors, Division of Translational
Toxicology
<bullet> Board of Scientific Counselors, National Cancer Institute
<bullet> Board of Scientific Counselors, National Center for
Complementary and Integrative Health
<bullet> Board of Scientific Counselors, National Eye Institute
<bullet> Board of Scientific Counselors, National Institute of
Arthritis and Musculoskeletal and Skin Diseases
<bullet> Board of Scientific Counselors, National Institute of
Biomedical Imaging and Bioengineering
<bullet> Board of Scientific Counselors, National Institute of Dental
and Craniofacial Research
<bullet> Board of Scientific Counselors, National Institute of Diabetes
and Digestive and Kidney Diseases
<bullet> Board of Scientific Counselors, National Institute of
Environmental Health Sciences
<bullet> Board of Scientific Counselors, National Institute of Mental
Health
<bullet> Board of Scientific Counselors, National Institute of
Neurological Disorders and Stroke
<bullet> Board of Scientific Counselors, National Institute on Aging
<bullet> Board of Scientific Counselors, National Institute on Alcohol
Abuse and Alcoholism
<bullet> Board of Scientific Counselors, National Institute on Deafness
and Other Communication Disorders
<bullet> Board of Scientific Counselors, National Institute on Drug
Abuse
<bullet> Board of Scientific Counselors, National Institute on Minority
Health and Health Disparities and National Institute of Nursing
Research
<bullet> Board of Scientific Counselors, National Library of Medicine
<bullet> Brain Disorders and Clinical Neuroscience Integrated Review
Group
<bullet> Cardiovascular and Respiratory Sciences Integrated Review
Group
<bullet> Cell Biology Integrated Review Group
<bullet> Center for Scientific Review Special Emphasis Panel
[[Page 14033]]
<bullet> Council of Councils
<bullet> Cures Acceleration Network Review Board
<bullet> Digestive, Kidney and Urological Systems Integrated Review
Group
<bullet> Division of Intramural Research Board of Scientific Counselors
National Institute of Allergy and Infectious Diseases
<bullet> Emerging Technologies and Training Neurosciences Integrated
Review Group
<bullet> Endocrinology, Metabolism, Nutrition and Reproductive Sciences
Integrated Review Group
<bullet> Fogarty International Center Advisory Board
<bullet> Genes, Genomes, and Genetics Integrated Review Group
<bullet> Healthcare Delivery and Methodologies Integrated Review Group
<bullet> Infectious Diseases and Immunology A Integrated Review Group
<bullet> Infectious Diseases and Immunology B Integrated Review Group
<bullet> Integrative, Functional and Cognitive Neuroscience Integrated
Review Group
<bullet> Interagency Autism Coordinating Committee
<bullet> Interagency Pain Research Coordinating Committee
<bullet> Interdisciplinary Molecular Sciences and Training Integrated
Review Group
<bullet> Molecular, Cellular and Developmental Neuroscience Integrated
Review Group
<bullet> Muscular Dystrophy Coordinating Committee
<bullet> Musculoskeletal, Oral, and Skin Sciences Integrated Review
Group
<bullet> National Advisory Allergy and Infectious Diseases Council
<bullet> National Advisory Board on Medical Rehabilitation Research
<bullet> National Advisory Child Health and Human Development Council
<bullet> National Advisory Council for Biomedical Imaging and
Bioengineering
<bullet> National Advisory Council for Complementary and Integrative
Health
<bullet> National Advisory Council for Human Genome Research
<bullet> National Advisory Council for Nursing Research
<bullet> National Advisory Council on Aging
<bullet> National Advisory Council on Alcohol Abuse and Alcoholism
<bullet> National Advisory Council on Drug Abuse
<bullet> National Advisory Council on Minority Health and Health
Disparities
<bullet> National Advisory Dental and Craniofacial Research Council
<bullet> National Advisory Environmental Health Sciences Council
<bullet> National Advisory Eye Council
<bullet> National Advisory General Medical Sciences Council
<bullet> National Advisory Mental Health Council
<bullet> National Advisory Neurological Disorders and Stroke Council
<bullet> National Arthritis and Musculoskeletal and Skin Diseases
Advisory Council
<bullet> National Cancer Advisory Board
<bullet> National Cancer Institute Clinical Trials and Translational
Research Advisory Committee
<bullet> National Cancer Institute Council of Research Advocates
<bullet> National Center for Advancing Translational Sciences Advisory
Council
<bullet> National Deafness and Other Communication Disorders Advisory
Council
<bullet> National Diabetes and Digestive and Kidney Diseases Advisory
Council
<bullet> National Heart, Lung, and Blood Advisory Council
<bullet> National Science Advisory Board for Biosecurity
<bullet> National Toxicology Program Board of Scientific Counselors
<bullet> National Toxicology Program Special Emphasis Panel
<bullet> NIH Clinical Center Research Hospital Board
<bullet> Office of AIDS Research Advisory Council
<bullet> Office of Research Infrastructure Programs Special Emphasis
Panel
<bullet> Oncology 1-Basic Translational Integrated Review Group
<bullet> Oncology 2-Translational Clinical Integrated Review Group
<bullet> Population Sciences and Epidemiology Integrated Review Group
<bullet> President's Cancer Panel
<bullet> Risk, Prevention and Health Behavior Integrated Review Group
<bullet> Scientific Advisory Committee on Alternative Toxicological
Methods
<bullet> Scientific and Technical Review Board on Biomedical and
Behavioral Research Facilities
<bullet> Scientific Management Review Board
<bullet> Sickle Cell Disease Advisory Committee
<bullet> Sleep Disorders Research Advisory Board
<bullet> Social and Community Influences on Health Integrated Review
Group
<bullet> Surgical Sciences, Biomedical Imaging and Bioengineering
Integrated Review Group
<bullet> Vaccine Research Center Board of Scientific Counselors
National Institute of Allergy and Infectious Diseases
<bullet> Vascular and Hematology Integrated Review Group
5. Justification that the information or advice provided by the
Federal advisory committee or subcommittee is not available from
another Federal advisory committee, another Federal Government source,
or any other more cost-effective and less burdensome source.
CTAC is essential to the conduct of NCI and NIH agency business
because it provides independent, expert scientific and programmatic
advice to the NCI Director on the conduct, oversight, and
implementation of the clinical trials and translational research
enterprise, which is one of NCI's largest and most complex investment
of public funds. It is the only programmatic cancer-related advisory
committee whose sole focus is clinical trials and translational
research. CTAC was formed pursuant to a 2005 recommendation from the
National Cancer Advisory Board for NCI to establish a committee
dedicated to clinical trials, given NCI's large investment in this area
of research. Other NCI boards and committees do not have the expertise
needed to provide in-depth, enterprise-wide advice to ensure
accountability and optimal use of taxpayer dollars for NCI's clinical
trials networks and associated infrastructure.
CTAC integrates key stakeholders to provide advice that will foster
a collaborative, efficient, and innovative system that enables the
timely translation of discoveries into benefits for cancer patients. No
other Federal advisory committee has the same sole focus on NCI's
clinical trials and translational research enterprise or provides
coordinated, external advice in this area.
CTAC's current work strengthens the clinical trials enterprise by
providing advice to help advance streamlined data collection, real-
world data integration, and pragmatic trial design, supporting NIH
priorities to reduce burden, improve efficiency, and accelerate
innovative cancer prevention, early detection, and treatment
approaches. CTAC serves the public interest by providing a transparent,
independent forum through which advice is provided to the NCI Director,
and visibility into NIH's cancer research activities is ensured.
Meetings are open to the public, and membership includes a broad range
of experts, including patient advocates.
6. If the consultation is a committee renewal, a summary of the
previous accomplishments of the committee and the reasons it needs to
continue
Since its inception, CTAC has played a central role in modernizing
and improving the efficiency of NCI's federally funded clinical trials
system.
[[Page 14034]]
The committee has provided invaluable advice on the restructuring of
NCI's clinical trials networks, establishing timelines for initiating
trials, harmonizing guidelines across programs, and evaluating clinical
trials portfolios to enhance NCI's already-productive clinical trials
program.
As the conduct of clinical trials has continued to evolve, CTAC has
helped NCI to address emerging challenges through a continuous
improvement approach and made important recommendations to NCI. CTAC
recommendations have focused on operational efficiency, trial cost and
complexity, prevention and symptom management, and health-related
quality of life across the portfolio, while also reviewing NCI's
clinical and translational research portfolios to identify gaps in
recalcitrant cancers such as pancreatic, lung, gastric, and
glioblastoma cancers. CTAC's recommendations have also informed
scientific frameworks, strengthened programs in cancer screening,
radiation oncology, quantitative imaging, and clinical trials
informatics, and revolutionized government-sponsored clinical trials,
enabling faster and more efficient delivery of outcomes to the American
public.
CTAC's impact extends beyond NCI by advancing collaboration and
improving clinical research practices across NIH and other federal
agencies. The scientific framework CTAC recommended for pancreatic
cancer led to cross-NIH collaborations, particularly for the early
diagnosis of pancreatic cancer and understanding the role of diabetes
in cancer etiology. NIH adopted principles of efficiency and
centralized trial operations advanced by CTAC to strengthen clinical
trial conduct. CTAC's advice also helped NCI to establish the NCI-VA
Interagency Group to Accelerate Trials Enrollment (NAVIGATE), which
contributed approximately 400 enrollments to NCI trials in 2025 and
expanded Veterans' access to cancer clinical trials.
If CTAC were discontinued, key stakeholders in clinical trials and
translational research would lose a voice in providing input on NCI's
scientific programs and initiatives, creating a void in NIH's ability
to better serve the public and achieve the administration's goal of
understanding and lowering chronic disease rates across the cancer
control spectrum, including prevention, early detection, and treatment.
7. Explanation of why the committee/subcommittee is essential to
the conduct of agency business
CTAC is essential to the conduct of NCI and NIH agency business
because it provides independent and expert advice that directly informs
how NCI manages its clinical trials and translational research
enterprise, an area that represents one of NCI's largest and most
complex investments of public funds. CTAC provides advice to the NCI
Director on the conduct, oversight, and implementation of clinical
trials and translational research across the Institute by providing
broad scientific and programmatic advice on the investment of taxpayer
dollars.
CTAC supports NCI's statutory mission and aligns with the current
administration's priorities by supporting a strong and efficient cancer
clinical trials research enterprise. Through independent, expert advice
on NCI-supported clinical trials and translational research across the
cancer control continuum, CTAC advances efforts to reduce the burden of
chronic disease, enhances transparency and stewardship of NIH's cancer
research investments, and promotes research aimed at lowering cancer
rates and improving population health.
In conclusion, this public interest determination documents that
renewing the committee is in the public interest, essential to the
conduct of agency business, and that the information to be obtained is
not already available through another advisory committee or source
within the Federal Government.
Inquiries may be directed to Patricia Brandt Hansberger, Acting
Director, Office of Federal Advisory Committee Policy, Office of the
Director, National Institutes of Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301)
496-2123, or <a href="/cdn-cgi/l/email-protection#5d2d3c292f343e343c73353c332e3f382f3a382f1d333435733a322b"><span class="__cf_email__" data-cfemail="05756471776c666c642b6d646b76676077626077456b6c6d2b626a73">[email protected]</span></a>.
Dated: March 20, 2026.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2026-05694 Filed 3-23-26; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 24, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.